Latest CervoMed News & Updates

See the latest news and media coverage for CervoMed. We track all announcements, press releases, and industry mentions in real time, all in one place.

CervoMed

Clinical-stage biotechnology company developing treatments for age-related brain disorders

cervomed.com

Headquarters: Boston, United States
Founded year: 2023
Company type: Public company
Number of employees: 20–50
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about CervoMed

In short: CervoMed advanced neflamapimod toward Phase 3 for dementia with Lewy bodies and shared initial Phase 2a data for frontotemporal dementia.

Company announcements

August 10 CervoMed

CervoMed reports Q2 2026 financial results and corporate updates

The company is prioritizing a strategic partnership to advance neflamapimod into Phase 3 for DLB, and presented new analyses at AAIC 2026.

August 4 CervoMed

CervoMed announces neflamapimod awarded UK Innovation Passport designation

The ILAP designation aims to accelerate UK market access and provides coordinated guidance from MHRA, NHS, and HTA bodies for the DLB treatment candidate.

July 14 CervoMed

CervoMed presents new clinical data for neflamapimod at AAIC 2026

New analyses reinforce treatment effect in pure DLB and support Phase 3 dose selection.

July 9 CervoMed

CervoMed completes enrollment in Phase 2 study for nfvPPA

Interim biomarker data accepted for CTAD presentation. No approved treatments exist for this FTD type.

Media coverage

September 11 ZoneBourse

Evolution de l'Objectif Moyen: CervoMed Inc.

18/03 CervoMed Inc. : Chardan Research réitère son opinion positive sur le titre ZM 18/12 CervoMed Inc. : Cantor Fitzgerald réajuste son opinion à la...

September 10 ZoneBourse

CervoMed announces the first results of the phase 2a clinical trial on neflamapimod in non-fluent primary progressive aphasia

CervoMed has recently completed recruitment for the phase 2a clinical trial on neflamapimod intended for the treatment of non-fluent primary progressive aphasia ...

August 13 Ticker Report

CervoMed Nears Phase III in Lewy Body Dementia as Neflamapimod Data Builds - Ticker Report

CervoMed (NASDAQ:CRVO) is positioning its lead candidate, neflamapimod, as a targeted treatment for dementia with Lewy bodies, or DLB, while advancing additional clinical programs in...

August 10 Markets Insider

CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the...

Never miss news about CervoMed

Track CervoMed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

CervoMed competitors & trending companies

Browse news for competitors to CervoMed and other trending companies.